Medscape
The antibody-drug conjugate ifinatamab deruxtecan (I-DXd) is effective in extensive-stage small cell lung cancer (ES-SCLC), with a higher dose of the drug almost doubling the response rate over a lower dose, suggests the phase 2 Ideate-lung01 study. The research, presented at the IASLC World Conference on Lung Cancer (WCLC) 2024 on September 8…
Read More
Ifinatamab Deruxtecan Effective in ES-SCLC
Zonia Redner
22:31
The antibody-drug conjugate ifinatamab deruxtecan (I-DXd) is effective in extensive-stage small cell lung cancer (ES-SCLC), with a higher dose of the drug almost doubling the response rate over a lower dose, suggests the phase 2 Ideate-lung01 study. The research, presented at the IASLC World Conference on Lung Cancer (WCLC) 2024 on September 8…
